EU/3/14/1423: Orphan designation for the treatment of plasma cell myeloma

Synthetic signal peptide of human mucin-1 (amino acids 1-21)

Overview

On 15 January 2015, orphan designation (EU/3/14/1423) was granted by the European Commission to Richardson Associates Regulatory Affairs Ltd, United Kingdom, for synthetic signal peptide of human mucin-1 (amino acids 1-21) for the treatment of plasma cell myeloma.

Key facts

Active substance
Synthetic signal peptide of human mucin-1 (amino acids 1-21)
Intended use
Treatment of plasma cell myeloma
Orphan designation status
Positive
EU designation number
EU/3/14/1423
Date of designation
15/01/2015
Sponsor

Turnkey Pharmaconsulting Ireland Limited

Ellerman House
5 Cratloe Woods
Brickhill West
Ennis
Co. Clare
V95 X925
Ireland

Email: markturner@TurnKeyPharmaConsulting.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

DateUpdate
June 2022The sponsorship was transferred to Turnkey Pharmaconsulting Ireland Limited, Ireland in June 2022.
December 2018The sponsorship was transferred to Richardson Associates Regulatory Affairs Ltd, Ireland, in December 2018.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating